StockData
Celldex Therapeutics, Inc. logo

Celldex Therapeutics, Inc. (CLDX) stock

CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$28.04−0.55 (-1.92%)

Close on Nov 17, 2026Market cap $2.20BP/E –Yield –

Celldex Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for Celldex Therapeutics

Celldex Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Celldex Therapeutics figures

See a number that looks wrong?